logo
Twitter
Discord
Email
logo
Immunocore Holdings plc

Immunocore Holdings plc

NASDAQ•IMCR
CEO: Dr. Bahija Jallal Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-02-05
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Contact Information
92 Park Drive, Milton Park, Abingdon, OX14 4RY, United Kingdom
44-12-3543-8600
www.immunocore.com
Market Cap
$1.68B
P/E (TTM)
-59.5
38.2
Dividend Yield
--
52W High
$40.72
52W Low
$23.15
52W Range
58%
Rank55Top 80.0%
2.6
F-Score
Modified Piotroski Analysis
Based on 7-year fundamentals
Weak • 2.6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2019-2025

Financial Dashboard

Q3 2025 Data

Revenue

$103.69M+29.22%
4-Quarter Trend

EPS

$0.02-91.33%
4-Quarter Trend

FCF

-$5.20M-125.64%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Therapy Sales Revenue Surge Net therapy sales revenue reached $295.5M USD, marking a strong 30.8% increase for nine months ended September.
Operating Loss Significantly Reduced Loss from operations improved substantially to $25.7M USD, down from $51.0M USD reported previously.
Cash Position Solidified Cash and cash equivalents grew to $498.4M USD, supporting near-term operational needs through current balances.
Pipeline Milestone Achieved IDMC recommended 160 mcg dose for registrational PRISM-MEL-301 Phase 3 trial, confirming path forward.

Risk Factors

R&D Spending Increased Total R&D expenses increased 21.5% to $196.0M USD due to pipeline advancement costs across programs.
Cumulative Losses Continue Accumulated deficit stands at $801.2M USD, reflecting ongoing need for external funding to support operations.
International Operations Exposure UK base exposes results to economic weakness, regulatory changes, and geopolitical tensions in foreign markets.
Tariff Impact Uncertainty Potential US/EU tariffs could increase cost of revenue, limiting margin flexibility on sales of KIMMTRAK.

Outlook

Commercial Expansion Ahead Continue KIMMTRAK commercial launch in additional territories where regulatory approvals have been secured.
Advance Key Programs Progressing three late-stage clinical programs, including PRAME-targeted brenetafusp trials through completion.
Fund Long-Term Needs Existing cash supports twelve months; intend to consider additional financing when market terms are favorable.
Manufacturing Commitments Noted Noncancellable manufacturing commitments total $20.1M USD, majority estimated paid within next twelve months.

Peer Comparison

Revenue (TTM)

Novavax, Inc.NVAX
$1.06B
+20.3%
Harmony Biosciences Holdings, Inc.HRMY
$825.94M
+21.1%
Immunocore Holdings plcIMCR
$379.59M
+27.8%

Gross Margin (Latest Quarter)

Viridian Therapeutics, Inc.VRDN
100.0%
+0.0pp
AbCellera Biologics Inc.ABCL
100.0%
+588.5pp
Immunocore Holdings plcIMCR
99.5%
+0.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
EWTX$2.90B-18.4-30.9%0.7%
VRDN$2.70B-9.0-52.6%4.1%
RCUS$2.19B-6.7-69.8%11.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
7.3%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
50%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 25, 2026
|
EPS:-$0.28
|
Revenue:-
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $103.69M+29.2%
    |
    EPS: $0.02-91.3%
    Beat
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $97.96M+29.9%
    |
    EPS: $-0.21-8.7%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 7, 2025|
    Revenue: $93.88M+33.2%
    |
    EPS: $0.10-120.4%
    Beat
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 26, 2025|
    Revenue: $247.77M-0.7%
    |
    EPS: $-1.02+9.7%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $80.25M+23.7%
    |
    EPS: $0.18+269.6%
    Beat
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 8, 2024|
    Revenue: $75.40M+24.7%
    |
    EPS: $-0.23-37.8%
    Beat
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $70.50M+28.1%
    |
    EPS: $-0.49+14.0%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 28, 2024|
    Revenue: $249.43M+73.5%
    |
    EPS: $-1.13-18.9%
    Miss